Zobrazeno 1 - 10
of 15
pro vyhledávání: '"33"'
Autor:
Carolien H. Smorenburg, Agnes Jager, Cynthia Holterhues, Tessa G Steenbruggen, Mark-David Levin, Marcel J.M. Kofflard, Hánah N. Rier, Eric Boersma, Gabe S. Sonke, Jan C. Drooger, Jos J. E. M. Kitzen, Paul de Jong, Marlies L. van Bekkum, Albert J. ten Tije, Nathalie I. Bouwer
Publikováno v:
Cancer Research. 81:PS13-21
Research objectives and rationale Trastuzumab greatly enhances the efficacy of treatment in HER2+ metastatic breast cancer (MBC). Due to its potential to induce cardiomyopathy, however, trastuzumab is contraindicated in patients with baseline left ve
Autor:
Erin Macrae Macrae, D Akuma, Charles L. Shapiro, Mahmoud Abdel-Rasoul, J Querry, DN Mullins, A Feng
Publikováno v:
Cancer Research. 73:P4-12
Background: Trastuzumab has become the cornerstone of adjuvant therapy for patients with HER2-positive breast cancer, as it has significantly impacted on overall survival for these patients. Unfortunately, not all patients are cured, and recurrences
Publikováno v:
Cancer Research. 81:1479-1479
Background: BRAF and MEK inhibitors are currently FDA approved for melanoma, non-small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600+ colorectal cancer (CRC) has prevented its tissue-a
Publikováno v:
Cancer Research. 76:4032-4050
A major objective of the emerging field of exercise–oncology research is to determine the efficacy of, and biological mechanisms by which, aerobic exercise affects cancer incidence, progression, and/or metastasis. There is a strong inverse associat
Autor:
Monica V. Estrada, Melinda E. Sanders, David B. Solit, Helen Won, Mellissa Hicks, IA Mayer, Justin M. Balko, Lew Cantley, Nancy Bouvier, M.F. Berger, CL Arteaga
Publikováno v:
Cancer Research. 76:P3-07
Background: Activation of the phosphoinositide-3-kinase (PI3K) pathway has been associated with resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer. Recently, we reported a Stand Up 2 Cancer (SU2C) Phase Ib trial of bupa
Autor:
Anne Barra, Florence Jacomet, Jean-Claude Chomel, Ali G. Turhan, André Herbelin, Stephane Flamant, Jean-Marc Gombert, Jean-Philippe Girard, Christine Giraud, Sara Basbous, Marie-Laure Bonnet, François Guilhot, Elvire Bourgeois, Olivier Feraud, Lydia Roy, Anaïs Levescot
Publikováno v:
Cancer Research. 74:2669-2676
Although it is generally acknowledged that cytokines regulate normal hematopoiesis in an autocrine/paracrine fashion, their possible role in chronic myelogenous leukemia (CML) and resistance to imatinib mesylate treatment remain poorly investigated.
Autor:
Rachel Stoddard, Dewey Kim, Mary McGillicuddy, Sara Balch, Ofir Cohen, Elana Anastasio, Beena Thomas, Colleen M. Nguyen, Jorge Buendia Buendia, Corrie A. Painter, Esha Jain, Nikhil Wagle, Michael Dunphy, S Di Lascio, RB Sousa, Brett N. Tomson
Publikováno v:
Cancer Research. 79:PD9-03
Background: Approximately 5-10% of newly diagnosed breast cancers (BC) are de novo MBC, which means that metastatic disease was identified at the time of initial diagnosis. Patients with de novo MBC are underrepresented in currently available genomic
Autor:
G Cornelio, Eun Mi Lee, SoHyun Lee, I-G Do, T Yau, KH Park, T-Y Kim, H-S Oh, J Tsang, Y-J Choi, S.-O. Lee, Y-S. Yap, E-M Yeoh, Suyeon Park, JH Lim, Gyungyup Gong, T-Y Ng, Soonmyung Paik, Jungsil Ro, S-B Kim
Publikováno v:
Cancer Research. 73:P4-12
Recent findings suggest that HER2-related molecular markers such as PTEN deletion or downregulation, PIK3CA mutation, truncated HER2 receptor (p95HER2), and tumor HER2 mRNA levels, have the potential to predict anti-HER2 treatment response. We evalua
Autor:
Masafumi Kurosumi, Izumi Takeyoshi, Mary Padilla, Shigenori Nagai, Katsunori Tozuka, Kenichi Inoue, Jun Horiguchi, Hanako Oba, Sasagu Kurozumi, Hiroshi Matsumoto, Hiroaki Nitta, Jim Ranger-Moore, Eslie Dennis, Yuji Hayashi
Publikováno v:
Cancer Research. 75:P2-04
Background: The eligibility of patients for HER2-targeted therapies is determined by the evaluation of HER2 gene amplification and HER2 protein overexpression. The gene-protein assay (GPA, Ventana Medical Systems, Inc., USA) is a new method for simul
Publikováno v:
Cancer Research. 77:5543-5543
Background: All-trans retinoic acid (ATRA) is a differentiating agent used in the treatment of acute-promyelocytic-leukemia and it is under-exploited in other malignancies despite its low systemic toxicity. A rational/personalized use of ATRA require